vimarsana.com

Latest Breaking News On - Astrazeneca truqap - Page 1 : vimarsana.com

Truqap recommended for EU breast cancer approval | Company Announcement

AstraZeneca s Truqap Plus Faslodex Recommended For EU Approval By CHMP For Advanced Breast Cancer

AstraZeneca s Truqap Plus Faslodex Recommended For EU Approval By CHMP For Advanced Breast Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or .

Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants (NASDAQ:AZN)

Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants (NASDAQ:AZN)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.